French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.

Autor: Garnham A; Astellas Pharma Europe Ltd., Addlestone, Surrey, UK. andrewrgarnham@gmail.com.; Clear Health Economics Ltd., Gateshaw Shillinglee Road, Plaistow, Billingshurst, Sussex, RH14 0PQ, UK. andrewrgarnham@gmail.com., Bruon F; Astellas Pharma S.A.S., Levallois-Perret, France., Berthon C; Centre Hospitalier Universitaire de Lille, Lille, France., Lebon D; Centre Hospitalier Universitaire d'Amiens, Amiens, France., Parimi M; IQVIA, London, UK., Polya R; IQVIA, London, UK., Makhloufi KM; Astellas Pharma S.A.S., Levallois-Perret, France., Dramard-Goasdoue MH; Astellas Pharma S.A.S., Levallois-Perret, France.

Publikováno v: Oncology and therapy [Oncol Ther] 2023 Sep; Vol. 11 (3), pp. 375-389. Date of Electronic Publication: 2023 Aug 14.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

Autor: Chouaid C; CHI Créteil, Créteil, France. Electronic address: Christos.chouaid@chicreteil.fr., Danson S; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom. Electronic address: s.danson@sheffield.ac.uk., Andreas S; Lungenfachklinik Immenhausen, Krs. Kassel and Universitätsmedizin Göttingen, 37075 Göttingen, Robert Koch Str. 40, Germany. Electronic address: stefan.andreas@med.uni-goettingen.de., Siakpere O; GSK, Middlesex, United Kingdom. Electronic address: obukohwo.2.siakpere@gsk.com., Benjamin L; GSK, Rueil-Malmaison, France. Electronic address: laurebenjamin29@gmail.com., Ehness R; GSK, Prinzregentenplatz 9, 81675 Munich, Germany. Electronic address: rainer.ehness@novartis.com., Dramard-Goasdoue MH; GSK, Marly le Roi cedex, France. Electronic address: mhdg@wanadoo.fr., Barth J; GSK, Munich, Germany. Electronic address: janina.barth@novartis.com., Hoffmann H; Thoraxklinik, University of Heidelberg, Heidelberg, Germany. Electronic address: hans.hoffmann@med.uni-heidelberg.de., Potter V; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. Electronic address: Vanessa.potter@uhcw.nhs.uk., Barlesi F; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Centre d'Investigation Clinique, 13385, Marseille, France. Electronic address: fabrice.barlesi@ap-hm.fr., Price M; RTI Health Solutions, Research Triangle Park, Durham, NC, United States. Electronic address: mprice@rti.org., Chirila C; RTI Health Solutions, Research Triangle Park, Durham, NC, United States. Electronic address: cchirila@rti.org., Hollis K; RTI Health Solutions, Research Triangle Park, Durham, NC, United States. Electronic address: khollis@rti.org., Sweeney C; RTI Health Solutions, Research Triangle Park, Durham, NC, United States. Electronic address: csweeney@rti.org., Wolowacz S; Health Economics, RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road Manchester, M20 2LS, United Kingdom. Electronic address: swolowacz@rti.org., Kaye JA; Epidemiology, RTI Health Solutions, Waltham, MA, United States. Electronic address: jkaye@rti.org., Kontoudis I; GSK, Rue de l'Institut, 89, Rixensart 1330, Belgium. Electronic address: iliaskontoudis@gmail.com.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2018 Oct; Vol. 124, pp. 310-316. Date of Electronic Publication: 2018 Aug 10.